This page is for health professionals only.

NO
I AM NOT
A HEALTHCARE PROFESSIONAL.
The Preventive Effect of Oxytocin on Retinopathy in Streptozotocin- Induced Diabetic Rats
PDF
Cite
Share
Request
Original Article
VOLUME: 49 ISSUE: 2
P: 68 - 72
April 2019

The Preventive Effect of Oxytocin on Retinopathy in Streptozotocin- Induced Diabetic Rats

Turk J Ophthalmol 2019;49(2):68-72
1. Ege University Faculty of Medicine, Department of Ophthalmology, İzmir, Turkey
2. İstanbul Bilim University Faculty of Medicine, Department of Physiology, İstanbul, Turkey
3. Ege University Faculty of Medicine, Department of Histology and Embryology, İzmir, Turkey
4. Ege University Faculty of Medicine, Department of Physiology, İzmir, Turkey
No information available.
No information available
Received Date: 17.05.2018
Accepted Date: 27.08.2018
Publish Date: 30.04.2019
PDF
Cite
Share
Request

ABSTRACT

Objectives:

The aim of this study was to investigate the impact of intravitreal and intraperitoneal use of oxytocin (OT) on retinopathy in streptozotocin-induced diabetic rats.

Materials and Methods:

Twenty-four 6-8-week-old adult male and female Sprague Dawley rats were used in the study. Diabetes was induced in the rats with a single injection of intraperitoneal streptozotocin. Diabetes was verified after 48 hours by measuring blood glucose levels of 260 mg/dl (14.4 mmol/L) or higher in diabetic rats. The rats were divided into 4 groups and treated as follows: intravitreal physiological saline group (0.01 mL saline weekly), intravitreal OT group (10 μU/μL OT weekly), intraperitoneal physiological saline group (1 mL daily), and intraperitoneal OT group (100 IU/kg OT daily). Hamilton syringes fitted with 27-gauge needles were used for intraperitoneal injections while 31-gauge needles were used for intravitreal injection. After 4 weeks of treatment the rats were euthanized to evaluate outer nuclear layer (ONL) thickness, vascular endothelial growth factor (VEGF) immunoexpression, and plasma VEGF levels from blood samples obtained by cardiac puncture.

Results:

Morphometric analysis of retinal cross-sections showed that intravitreal and intraperitoneal OT significantly increased ONL thickness compared to physiological saline-treated groups. Also, OT treatment significantly decreased VEGF protein expression compared with the physiological saline groups. Plasma VEGF level was significantly higher in the physiological saline treatment group compared to the OT treatment group.

Conclusion:

OT reduces diabetic retinopathy progression, particularly when administered intravitreally. To our knowledge, this is the first attempt to investigate the impact of OT on diabetic retinopathy and may provide a new area for further research.

Keywords:
Immunohistochemistry, oxytocin, retinopathy, streptozotocin, VEGF

Introduction

Diabetes mellitus is a progressive disease that afflicts over 230 million people worldwide. Diabetes affects both microvascular and macrovascular structures throughout the body and consequently can cause retinopathy, neuropathy, and nephropathy. Diabetic retinopathy (DR) is the leading cause of preventable blindness. Sustained hyperglycemia causes the blood vessels to swell and leak fluid, resulting in damage to the microvascular structure of the retina. This can result in retinal ischemia that leads to vascular endothelial growth factor (VEGF) secretion and the growth of immature, fragile new vessels. These new vessels lead to neovascularization and proliferative DR and result in macular edema, vitreous hemorrhages, and tractional retinal detachment.1,2,3,4,5

Oxytocin (OT) is nonapeptide synthesized in the supraoptic and paraventricular nuclei of the hypothalamus. OT establishes its effects through the OT receptor, a G protein-coupled receptor. It stimulates uterine contractions at parturition, myoepithelial cell contraction in mammalian glands for milk ejection, and also has vasoconstrictor or vasodilator effects on different vascular beds.6,7,8 Recent studies have also reported the anti-inflammatory and anti-oxidant effects of OT.9,10 OT receptors have been found in cone photoreceptors and retinal pigment epithelium. OT exerts its effects by increasing intracellular levels of Ca+2, which facilitates smooth muscle contraction, nitric oxide synthesis, prostaglandin production, activation of the MAP-kinase cascade, and protein synthesis.11,12

In view of these previous studies and observations, we aimed to detect the effect of intravitreal and intraperitoneal administration of OT in the retina of streptozotocin (STZ)-induced diabetic rats.

Materials and Methods

Results

VEGF protein expression was examined by immunohistochemistry and ONL thickness was measured. The expression was scored as follows: 0 represented no expression while 1, 2, and 3 represented expressions of 0-24%, 25-49%, 50-74%, and >75%. All comparisons of ONL measurements and staining intensities were carried out at X40 magnification from 10 different sections.

Discussion

To the best of our knowledge, this is the first report describing the effects of OT on the retina of diabetic rats. The study revealed that OT has protective effects on diabetic rat retina, as evidenced by reduced VEGF protein expression and plasma VEGF levels, as well as prevention of outer nuclear layer thinning.

As the pathogenesis of DR is better understood, novel treatment options are likely to become available. Postulated mechanisms of DR are hyperglycemia, accumulation of advanced glycation end-products (AGEs), activation of protein kinase C, oxidative stress, and inflammation. Chronic hyperglycemia results in the production of reactive oxygen species, and low-grade inflammation. This induces apoptosis of the retinal pigment epithelium and progression of DR. Hyperglycemia also causes accumulation of AGEs beneath the endothelial layer and changes the vascular structure, increases vascular stiffness, and initiates intracellular signaling pathways that lead to increased oxidative stress and inflammation. Oxidative stress is considered to be the most common mechanism in the etiology of DR. Damage or dysfunction due to oxidative stress can proceed even after glycemic control. Inflammation also plays an important role in the progression of DR and its complications. Therefore, new treatment strategies should be developed that target oxidative stress and inflammation.1,13,14,15,16,17,18,19,20

OT is nonapeptide and its receptors have been identified in different tissues including kidney, heart, pancreas, adipocytes, and thymus. The role of OT in immune and inflammatory modulation is well defined and attributed to the activation of its receptors.6,7,8,21 Based on these studies, we hypothesized that OT may act as an antioxidant and anti-inflammatory agent and therefore serve as a therapeutic agent in DR. Cone photoreceptors and the retinal pigment epithelium have OT receptors. Activation of those receptors causes an increase in intracellular Ca+2 level and downstream activation of phospholipase C and phosphatidylinositol 4,5-bisphosphate.13,14

In diabetic patients, sustained hyperglycemia can cause dysregulation in retinal blood flow, loss of pericytes, basal membrane thickening, microaneurysms, capillary occlusion, and ischemia. Ischemia eventually leads to the production of VEGF that activates tyrosine kinase receptors, VEGFR-1 and VEGFR-2.22 VEGF is a growth factor and potent vasoactive cytokine that promotes angiogenesis, breakdown of the blood-retinal barrier, and induces endothelial cell growth and neovascularization.23,24 Matsuoka et al.25 reported that expression of VEGF in diabetic retinas was significantly increased while Funatsu et al.26 suggested that VEGF levels in vitreous and plasma were elevated in diabetic patients with retinopathy when compared to normal subjects and diabetic patients without retinopathy. Consistent with this opinion, Aiello et al.27 found that VEGF concentration was elevated in the ocular fluids of patients with retinal ischemia. The present study showed that VEGF expression in retina and plasma VEGF levels were elevated, but with OT treatment, the expression and plasma levels were significantly decreased.

Thinning of the outer nuclear layer has been reported in diabetic rats. A number of studies have implicated apoptosis for the thinning effect.28,29,30 In the present study, in accordance with published reports, administration of OT was found to prevent the thinning of the ONL in STZ-induced diabetic rats when compared to the physiological saline group.

Conclusion

In conclusion, the treatment of STZ-induced diabetic rats with OT was effective in mitigating retinal degeneration. The significant reduction in VEGF expression and plasma VEGF levels and the protective effect against retinal thinning suggest that OT may be an alternative treatment in diabetic retinopathy. The beneficial effects of OT in diabetic retinal degeneration might be through its anti-oxidative and anti-inflammatory effects. To our knowledge this is the first report about the effect of OT on the retina of diabetic rats, and this subject needs to be explored with further studies.

References

1
Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res. 2007;2007:43603. [PMC free article] [PubMed] [Google Scholar]
2
Semeraro F, Cancarini A, dell’Omo R, Rezzola S, Romano MR, Costagliola C. Diabetic Retinopathy: Vascular and Inflammatory Disease. J Diabetes Res. 2015;2015:582060. [PMC free article] [PubMed] [Google Scholar]
3
Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12:346–354. [PubMed] [Google Scholar]
4
Stewart MW. The clinical utility of aflibercept for diabetic macular edema. Diabetes Metab Syndr Obes. 2015;8:473–482. [PMC free article] [PubMed] [Google Scholar]
5
Behl T, Kaur I, Kotwani A. Implication of oxidative stress in progression of diabetic retinopathy. Surv Ophthalmol. 2016;61:187–196. [PubMed] [Google Scholar]
6
Iseri SO, Sener G, Sağlam B, Gedik N, Ercan F, Yeğen BC. Oxytocin ameliorates oxidative colonic inflammation by a neutrophil-dependent mechanism. Peptides. 2005;26:483–491. [PubMed] [Google Scholar]
7
Akman T, Akman L, Erbas O, Terek MC, Taskiran D, Ozsaran A. The preventive effect of oxytocin to Cisplatin-induced neurotoxicity: an experimental rat model. Biomed Res Int. 2015;2015:167235. [PMC free article] [PubMed] [Google Scholar]
8
Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81:629–683. [PubMed] [Google Scholar]
9
Rashed LA, Hashem RM, Soliman HM. Oxytocin inhibits NADPH oxidase and P38 MAPK in cisplatin-induced nephrotoxicity. Biomed Pharmacother. 2011;65:474–480. [PubMed] [Google Scholar]
10
Erbas O, Ergenoglu AM, Akdemir A, Yeniel AÖ, Taskiran D. Comparison of melatonin and oxytocin in the prevention of critical illness polyneuropathy in rats with experimentally induced sepsis. J Surg Res. 2013;183:313–320. [PubMed] [Google Scholar]
11
York N, Halbach P, Chiu MA, Bird IM, Pillers DM, Pattnaik BR. Oxytocin (OXT)-stimulated inhibition of Kir7.1 activity is through PIP(2)-dependent Ca(2+) response of the oxytocin receptor in the retinal pigment epithelium in vitro. Cell Signal. 2017;37:93–102. [PMC free article] [PubMed] [Google Scholar]
12
Halbach P, Pillers DA, York N, Asuma MP, Chiu MA, Luo W, Tokarz S, Bird IM, Pattnaik BR. Oxytocin expression and function in the posterior retina: a novel signaling pathway. Invest Ophthalmol Vis Sci. 2015;15;56:751–760. [PMC free article] [PubMed] [Google Scholar]
13
Wan TT, Li XF, Sun YM, Li YB, Su Y. Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. Biomed Pharmacother. 2015;74:145–147. [PubMed] [Google Scholar]
14
Wang XL, Yu T, Yan QC, Wang W, Meng N, Li XJ, Luo YH. AGEs Promote Oxidative Stress and Induce Apoptosis in Retinal Pigmented Epithelium Cells RAGE-dependently. J Mol Neurosci. 2015;56:449–460. [PubMed] [Google Scholar]
15
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615–1625. [PubMed] [Google Scholar]
16
Chen M, Curtis TM, Stitt AW. Advanced glycation end products and diabetic retinopathy. Curr Med Chem. 2013;20:3234–3240. [PubMed] [Google Scholar]
17
Yu Y, Chen H, Su SB. Neuroinflammatory responses in diabetic retinopathy. J Neuroinflammation. 2015;12:141. [PMC free article] [PubMed] [Google Scholar]
18
Kowluru RA, Mishra M. Oxidative stress, mitochondrial damage and diabetic retinopathy. Biochim Biophys Acta. 2015;1852:2474–2483. [PubMed] [Google Scholar]
19
Zong H, Ward M, Stitt AW. AGEs, RAGE, and diabetic retinopathy. Curr Diab Rep. 2011;11:244–252. [PubMed] [Google Scholar]
20
Deliyanti D, Zhang Y, Khong F, Berka DR, Stapleton DI, Kelly DI, Wilkinson-Berka JL. FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy. PLoS One. 2015;10:e0134392. [PMC free article] [PubMed] [Google Scholar]
21
Petersson M, Wiberg U, Lundeberg T, Uvnas-Moberg K. Oxytocin decreases carrageenan induced inflammation in rats. Peptides. 2001;22:1479–1484. [PubMed] [Google Scholar]
22
Osaadon P, Fagan XJ, Lifshitz T, Levy J. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye (Lond). 2014;28:510–520. [PMC free article] [PubMed] [Google Scholar]
23
Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2013;2013:343560. [PMC free article] [PubMed] [Google Scholar]
24
Kastelan S, Tomic M, Gverovic Antunica A, Salopek Rabatic J, Ljubic S. Inflammation and pharmacological treatment in diabetic retinopathy. Mediators Inflamm. 2013;2013:213130. [PMC free article] [PubMed] [Google Scholar]
25
Matsuoka M, Ogata N, Minamino K, Matsumura M. Expression of pigment epithelium-derived factor and vascular endothelial growth factor fibrovascular membranes from patients with proliferative diabetic retinopathy. Jpn J Ophthalmol. 2006;50:116–120. [PubMed] [Google Scholar]
26
Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol. 2002;133:537–543. [PubMed] [Google Scholar]
27
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–1487. [PubMed] [Google Scholar]
28
Boretsky A, Gupta P, Tirgan N, Liu R, Godley BF, Zhang W, Tilton RG, Motamedi M. Nicotine accelerates diabetes-induced retinal changes. Curr Eye Res. 2015;40:368–377. [PMC free article] [PubMed] [Google Scholar]
29
Zhang J, Wu Y, Jin Y, Ji F, Sinclair SH, Luo Y, Xu G, Lu L, Dai W, Yanoff M, Li W, Xu GT. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci. 2008;49:732–742. [PubMed] [Google Scholar]
30
Park SH, Park JW, Park SJ, Kim KY, Chung JW, Chun MH, Oh SJ. Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia. 2003;46:1260–1268. [PubMed] [Google Scholar]